KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Total Debt (2016 - 2020)

Neogenomics (NEO) has disclosed Total Debt for 11 consecutive years, with $95.6 million as the latest value for Q1 2020.

  • For the quarter ending Q1 2020, Total Debt rose 642.68% year-over-year to $95.6 million, compared with a TTM value of $95.6 million through Mar 2020, up 642.68%, and an annual FY2019 reading of $96.8 million, up 652.19% over the prior year.
  • Total Debt was $95.6 million for Q1 2020 at Neogenomics, down from $96.8 million in the prior quarter.
  • Across five years, Total Debt topped out at $99.3 million in Q3 2019 and bottomed at $12.9 million in Q4 2018.
  • Average Total Debt over 5 years is $65.3 million, with a median of $71.3 million recorded in 2017.
  • Peak annual rise in Total Debt hit 652.19% in 2019, while the deepest fall reached 81.46% in 2019.
  • Year by year, Total Debt stood at $25.5 million in 2016, then increased by 10.63% to $28.3 million in 2017, then crashed by 54.46% to $12.9 million in 2018, then surged by 652.19% to $96.8 million in 2019, then fell by 1.26% to $95.6 million in 2020.
  • Business Quant data shows Total Debt for NEO at $95.6 million in Q1 2020, $96.8 million in Q4 2019, and $99.3 million in Q3 2019.